From "anti-infection" to "anti-severe disease" The exchange meeting on treatment plans for elderly patients with severe disease infected with new crown infection was held, and new combination
Time of Update: 2023-02-01
Professor Yang Jiankun of Fuxing Hospital Affiliated to Capital Medical University introduced that the use of antiviral drugs in the early stage of new crown diagnosis and treatment can significantly reduce viral load, which is of great significance for disease control; In addition, if the early inflammatory response caused by new coronavirus infection is not controlled in time, it may bring difficulties to subsequent treatment, and early application of glucocorticoids and tocilizumab is particularly necessary.
ESMO Strikes Directly at the Scene After the progress of first-line treatment, the results of "re-challenge" immunotherapy were unveiled at ESMO: the first phase III study
Time of Update: 2022-10-02
Details are as follows: Professor Mustafa Ozguroglu1 backgroundThe EMPOWER-Lung 1 study showed that cemiplimab first-line monotherapy for advanced NSCLC significantly improved patient survival (OS) and had an acceptable safety profile compared with chemotherapy.
National Cancer Center Releases: 2022 National Cancer Report
Time of Update: 2022-04-28
In February 2022, the National Cancer Center released the latest edition of the National Cancer Statistics . The National Cancer Registry Center is responsible for the collection, quality control,
Time of Update: 2022-02-23
mRNA boosters induce neutralizing immunity against Omicron Current vaccines against Omicron variants have been reported to be less protective compared to the previous worrisome variant (VOC), but they may still provide some protection .
Nat Commum: Fearless of mutations, the Chinese team revealed that exosomes can be used as bait to block a variety of new crown mutants
Time of Update: 2022-02-20
Extracellular vesicles that carry the ACE2 protein The more severely ill patients have higher blood levels of evACE2These ACE2-expressing extracellular vesicles (evACE2) were able to block the infection of cells by different coronavirus variants in vitro .
Three articles on Immunity Z-RNA editing restrict innate immunity from recognizing endogenous RNA
Time of Update: 2021-11-15
It was found that these mice spontaneously induce type I IFNs and ISGs in multiple organs and cell types, suggesting that Z-RNA editing is restricting the recognition of endogenous RNA by innate immunity The important role of aspects .
Hengrui Pharmaceuticals PD-L1 in the treatment of extensive-stage small cell lung cancer phase III clinical study reached the primary endpoint
Time of Update: 2021-11-15
Recently, Hengrui Medicine's new class 1 drug PD-L1 monoclonal antibody SHR-1316 (Adbelizumab injection) combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer is a randomized, double-blind, placebo-controlled, multi-center phase III The main research endpoint of the clinical study (SHR-1316-III-301) reached the pre-specified superiority standard .
Nature's heavyweight: Overcoming the problem of bacterial resistance, a new type of synthetic antibiotic may become the "nemesis" of resistant bacteria
Time of Update: 2021-11-12
Previous studies have shown that bacteria can be infected by special chemical modification of the nucleotides at the ribosomal drug-binding site — methylation, which changes the conformation of the binding site so that the drug cannot bind to the ribosome, thus gaining resistance.
Application of medical antibacterial coating in implant infection
Time of Update: 2021-04-27
The preparation of high-load antibacterial agent and long-term controlled release endophyte coating is one of the research directions of antibacterial coatings in the future, and it is of great significance for the prevention of biological material-related infections.
Nat Commun: Predicting Clostridium difficile infection based on microbiota markers
Time of Update: 2021-04-22
The results of this study have been validated in an independent CDI prospective patient cohort , which can be used to enrich high-risk patients in prospective clinical trials and develop microbiota-based predictive diagnostic methods for the management of CDI risk patients.
Inhalation interferon beta sNG001 reduces the risk of COVID-19 developing into severe illness
Time of Update: 2020-07-27
Synairgen, !---- a pharmaceutical company, announced today that its inhaled interferon beta sNG001 treatment of patients with COVID-19 significantly reduces the risk of serious illness compared to a p
Breakthrough! Prevention of heart attacks has new flora or can predict "heart" signals
Time of Update: 2020-06-02
In the study, the researchers included 30 patients with acute coronary artery syndrome and 10 patients with stable angina The researchers isolated the gut bacteria from their stool samples and extract
Increased capacity to prevent TB infection
Time of Update: 2020-05-31
Kaji Miao is the only approved TB vaccine It is a live seedling made of detoxifying bovine TB suspension, which has the ability to enhance macrophages activity, strengthen macrophages to kill tumor ce
Hot spot analysis of ESMO tumor conference in 2019
Time of Update: 2019-10-24
Tumor, as a chronic disease that has plagued human beings for many years and is becoming more and more rampant, its research progress can be said to affect everyone's heart ESMO annual meeting is one
[quick news] 10 billion biological products were modified, affecting 26 enterprises
Time of Update: 2019-01-17
Recently, the State Food and Drug Administration issued a notice to revise the instructions for intravenous human immunoglobulin (pH4) and freeze-dried intravenous human immunoglobulin (pH4), mainly a